CoreAge Rx vs No BS RX
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and No BS RX head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 87 on our six-factor Brief Score — One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
That doesn't make No BS RX a bad call — it's best for a reader who wants every term and every dose level comparable without starting an intake to see a price. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | No BS RX | |
|---|---|---|
| Brief Score | 94/100 (A) | 87/100 (B+) |
| Semaglutide | $99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not published | $179/mo month-to-month (compounded) |
| Tirzepatide | $149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not published | $249/mo month-to-month (compounded) |
| Coverage | US only; restrictions by state, confirmed at intake | Not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: Headline unchanged for a third straight cycle. The $99 and $149 are the 12-month prepay rates; CoreAge publishes no month-to-month price.
No BS RX: New to the tracker on 13 September 2026, read live off the provider's own pages that day rather than taken on trust. There is no earlier reading here to compare against, so the direction is "new" rather than stable — a first observation is not a trend. This is the one row where the thing to track is whether a promise holds: the page commits to no intro rate, and today the arithmetic agrees with it. A later reading either confirms that or is the story.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.